文献速递心力衰竭与心肌病

丹麦全国多中心双盲随机试验:心衰双心室起搏中左室导线靶向最新电激动部位

Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark.
PubMed 文献 · Lancet · 2026-08-31

该丹麦全国多中心双盲随机优效试验纳入符合双心室起搏适应证的1001例心衰合并宽QRS患者,比较左室导线置于冠状窦分支内最新电激动部位与常规后侧壁非心尖部位的结局。

要点

  • 左室导线靶向最新电激动部位未降低死亡或首次非计划心衰住院风险。
  • 两组总体并发症风险相似,但干预组导线相关并发症更常见。
  • 常规后侧壁非心尖部位仍可作为左室导线放置的合理选择。

核心结论

  • 在心衰合并宽QRS患者中,与常规后侧壁非心尖部位放置相比,左室导线靶向最新电激动部位未降低死亡或非计划心衰住院复合终点风险。

研究设计与样本

  • 丹麦全国五家大学中心开展的多中心、随机、对照、双盲、优效性试验。
  • 纳入2018年3月20日至2024年6月3日期间共1001例患者,随机分配499例至干预组、502例至对照组。
  • 1例错误入组患者被排除,最终1000例进入改良意向治疗分析。

主要发现

  • 干预组左室导线处电激动时间平均比对照组晚9毫秒(95% CI 5–13)。
  • 总体并发症风险两组相似,干预组71例(14%),对照组64例(13%)。
  • 导线相关并发症在干预组更常见。
  • 干预组发生1例与操作相关的死亡。

临床怎么用

  • 常规左室导线放置于后侧壁非心尖分支仍是可接受的标准做法。
  • 为追求电激动最晚部位而进行靶向放置可能增加导线相关并发症风险。

局限性

  • 排除标准、具体药物使用及合并症等原文未提供细节,无法进一步分析组间基线差异。
  • 原文未报告导线相关并发症的具体类型和发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular lead position is a key determinant of optimal biventricular pacing for heart failure. Observational data indicate better outcomes in patients with late myocardial activation at the left ventricular lead site. We aimed to test whether targeting the left ventricular lead at site of latest electrical activation improves outcomes. METHODS: In this national, randomised, controlled, double-blinded, superiority trial we included patients from all five Danish university centres performing device implantation who had heart failure and wide QRS on guideline-directed medication, eligible for biventricular pacing. We randomly assigned (1:1) patients to either the intervention group, with left ventricular lead placement at the latest electrically activated site within the coronary sinus branches, or to control group, with left ventricular lead placement in a posterolateral non-apical branch. Primary outcome was a composite of time to death or first unplanned heart failure hospitalisation. We used block randomisation and masked patients and all study personnel (except operating room personnel) to treatment allocation. The primary outcome was a composite of time to death or first unplanned hospitalisation for heart failure. Analysis followed a modified intention-to-treat approach. Safety was assessed in all correctly assigned patients. The trial is registered at ClinicalTrials.gov (NCT03280862) and is complete. FINDINGS: From March 20, 2018, to June 3, 2024, we included 1001 patients (255 females and 746 males); 499 were randomly assigned to the intervention group and 502 to the control group. One incorrectly enrolled patient was excluded, leaving 1000 patients for the modified intention-to-treat analysis. Electrical activation at left ventricular lead was a mean of 9 milliseconds (95% CI 5-13) later in the intervention group. Follow-up was completed on Feb 27, 2026, after a median 45·8 months (IQR 28·5-65·7). The primary endpoint occurred in 139 (28%) of 499 patients in the intervention group and 128 (26%) of 501 in control group (hazard ratio 1·10 [95% CI 0·86-1·39]; p=0·45). Overall complication risk was similar between groups (71 [14%] patients in the intervention group vs 64 [13%] in the control group), but lead-related complications were more frequent in the intervention group. One procedure-related death occurred in the intervention group. INTERPRETATION: In patients with heart failure and prolonged QRS, targeted left ventricular lead placement at the site of latest electrical activation did not reduce the composite endpoint of death or unplanned hospitalisation for heart failure compared with conventional lead placement in a posterolateral, non-apical position. FUNDING: Novo Nordisk Foundation, Danish Heart Foundation, Danish Pacemaker and ICD Registry, and Independent Research Fund Denmark.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Nielsen, Svendsen, Johansen, et al. Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark. Lancet. 2026. PMID: 42673980. doi:10.1016/S0140-6736(26)01597-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。